HilleVax, Inc. (NASDAQ:HLVX) Given Average Rating of "Hold" by Brokerages

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) has received an average rating of "Hold" from the six ratings firms that are presently covering the firm, MarketBeat reports. Six research analysts have rated the stock with a hold rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.00.

Separately, HC Wainwright reiterated a "neutral" rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st.

Institutional Investors Weigh In On HilleVax

A number of hedge funds have recently bought and sold shares of HLVX. Barclays PLC lifted its position in HilleVax by 255.6% in the third quarter. Barclays PLC now owns 42,033 shares of the company's stock worth $74,000 after purchasing an additional 30,213 shares during the period. SG Americas Securities LLC increased its stake in shares of HilleVax by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after buying an additional 6,916 shares in the last quarter. Ieq Capital LLC raised its holdings in shares of HilleVax by 71.1% in the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock valued at $47,000 after buying an additional 9,344 shares during the last quarter. Intech Investment Management LLC acquired a new position in HilleVax during the 4th quarter worth about $26,000. Finally, JPMorgan Chase & Co. lifted its position in HilleVax by 1,376.8% during the 4th quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company's stock worth $429,000 after buying an additional 193,124 shares in the last quarter. 86.42% of the stock is currently owned by institutional investors.

HilleVax Stock Down 1.0%

Shares of HLVX opened at $1.95 on Tuesday. The firm has a market cap of $97.77 million, a price-to-earnings ratio of -0.63 and a beta of 0.78. The company's fifty day moving average is $1.72 and its 200-day moving average is $1.84. HilleVax has a 12 month low of $1.34 and a 12 month high of $15.82.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.25. As a group, research analysts predict that HilleVax will post -2.64 earnings per share for the current fiscal year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.